Insights & Discussion
Combined Ma Huang Fu Zi Xi Xin decoction and Shen Mai injection treatment showed improved heart rate and symptoms in under 60s with bradyarrhythmia
Using Ma Huang Fu Zi Xi Xin decoction along with Shen Mai injection (SMI) treatment is better than just SMI treatment for patients under 60 with bradyarrhythmia. This combo improves heart rate and reduces symptoms, with no major side effects. The combination's effectiveness might come from shared heart-rate boosting components. However, there were differences in heart rate data due to varied ECG analysis.
Discover Related Insights
HuoXiang ZhengQi (HQXXD) may be a safe and effective treatment for Chronic Cough Variant Asthma (CVA), improving clinical efficacy and airway responsiveness while reducing recurrence rates.
2022 Evidence-Based Complementary and Alternative Medicine The Effectiveness and Safety of Huangqi Xixin Decoction for Cough Variant Asthma: A Systematic Review and Meta-Analysis Wang C, Xia Q, Hu B, Jiang W, Zhang H
Systematic Review Asthma Cough Huang Qi
HuoXiang ZhengQi (HQXXD) for Chronic Cough Variant Asthma (CVA) was systematically evaluated. The HQXXD group showed significantly higher total effective rates of clinical efficacy and airway responsiveness compared to the control group, while the recurrence rate was lower. Adverse reactions were not reported in HQXXD treatment, indicating its safety for CVA patients.
Asthma severity can be notably reduced by Xi Xin essential oil, which decreases inflammation, immunoglobulins, and fibrotic mediators, while also alleviating airway obstruction.
2022 Pharmaceutics Exploring the Potential Effects and Mechanisms of Asarum sieboldii Radix Essential Oil for Treatment of Asthma Han JM, Kim MH, Choi LY, Kim G, Yang WM
Network Pharmacology Asthma Xi Xin
AEO was administered via a nebulizer for three weeks ahead of exposing mice to ovalbumin (OVA), a protein commonly used to provoke an allergic reaction, and particulate matter (PM), common air pollutants. Co-treatment of AEO, OVA, and PM was carried out for four weeks. Additionally, A549 lung epithelial cells were exposed to PM to study the influence of AEO on lung-fibrosis-related factors.
In our study, we found that AEO notably inhibited goblet cell accumulation, which led to a decrease in epithelial thickness. Collagen deposition in lung tissues, a common marker of airway remodeling, was significantly inhibited by AEO in asthmatic mice exposed to OVA and PM. AEO also lessened the influx of inflammatory cells into the bronchoalveolar lavage fluid, an indicator of respiratory inflammation. Similarly, the increases in serum IgE and IgG, immunoglobulins associated with allergic reactions, and cytokines in lung tissues were reduced by AEO. Moreover, AEO successfully managed the expression of key fibrotic mediators, particularly POSTN and TGF-β. All these indicators point to AEO's potential as a promising therapeutic treatment to alleviate asthma symptoms.